JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD

Overview

JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD is an active pharmaceutical ingredient (API) supplier with 23 active FDA Type II Drug Master Files, covering RECOMBINANT ANTI-HUMAN CD16 MAB; RECOMBINANT ANTI-HUMAN CD28 MAB; RECOMBINANT ANTI-HUMAN CD3 MAB; RECOMBINANT HUMAN ACTIVIN A; RECOMBINANT HUMAN BFGF; RECOMBINANT HUMAN BMP 2.

API / Drug Master Files

JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD holds 23 active (23 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• RECOMBINANT HUMAN TRANSFERRINActive2025-08-13
• RECOMBINANT HUMAN M-CSF (E. COLI-EXPRESSED)Active2025-07-17
• RECOMBINANT HUMAN INTERLEUKIN-7Active2025-03-27
• RECOMBINANT HUMAN IL-18 (E.COLI-EXPRESSED)Active2025-03-27
• RECOMBINANT HUMAN BMP 2Active2025-03-27
• RECOMBINANT HUMAN IFNYActive2025-03-05
• RECOMBINANT ANTI-HUMAN CD3 MABActive2025-03-04
• RECOMBINANT HUMAN IL-1A (E.COLI-EXPRESSED)Active2025-02-24
• RECOMBINANT HUMAN G-CSFActive2024-09-24
• RECOMBINANT HUMAN GM-CSFActive2024-09-21
• RECOMBINANT HUMAN INTERLEUKIN-12Active2024-09-20
• RECOMBINANT HUMAN BFGFActive2024-09-11
• RECOMBINANT HUMAN PDGF-BBActive2024-09-08
• RECOMBINANT HUMAN TPOActive2024-09-07
• RECOMBINANT ANTI-HUMAN CD28 MABActive2024-09-04

Showing 15 of 23 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.